title: [Introduction and consideration of the anti-cancer drug evaluation strategy in Europe and America].
authors.forename: Jian-yuan
authors.initials: JY
authors.lastname: Tang
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000970:Antineoplastic Agents / Q000592:standards* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D018572:Disease-Free Survival; D005060:Europe; D005069:Evaluation Studies as Topic; D006077:Government Agencies; D006801:Humans; D020714:Maximum Tolerated Dose; D009369:Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D012074:Remission Induction; D015996:Survival Rate; D017211:Treatment Failure; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents